Fecal Microbiota Transfer in Acute Graft-versus-Host Disease following Allogeneic Stem Cell Transplantation.
Visc Med
2024
40
4
1-6
Optimal use of granulocyte colony-stimulating factor prophylaxis to improve survival in cancer patients receiving treatment : An expert view.
Wien Klin Wochenschr
2024
136
11-12
362-368
Predicting resistance and pseudoprogression: are minimalistic immunoediting mathematical models capable of forecasting checkpoint inhibitor treatment outcomes in lung cancer?
Math Biosci
2024
376
Unraveling the role of local ablative therapies for patients with metastatic soft tissue sarcoma - A retrospective multicenter study of the Bavarian university hospitals.
Eur J Surg Oncol
2024
50
12
Correction: Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19.
Clin Cancer Res
2024
30
10
2286-2286
Clinician Scientist Program Prognostic Markers for Stem Cell Transplantation
Inn Med (Heidelb)
2024
65
4
390-391
Lipocalin-2 expression identifies an intestinal regulatory neutrophil population during acute graft-versus-host disease.
Sci Transl Med
2024
16
735
Correction: Real‑world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC‑FFM in ruxolitinib‑refractory acute graft‑versus‑host disease.
J Transl Med
2024
22
1
Bone marrow transplantation reduces FGF-23 levels and restores bone formation in myelodysplastic neoplasms.
Leukemia
2024
38
8
1853-1857
VEXAS syndrome: complete molecular remission after hypomethylating therapy.
Ann Hematol
2024
103
3
993-997